A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation

European Journal of Pharmacology

Volumn 609, Issue 1-3, 2009, Pages 96-99

  Galliard Grigioni, Katja S ^a   Reinhart, Walter H ^a  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

Acetaminophen; Acetylsalicylic acid; Diclofenac; NSAID; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; NAPROXEN; NAPROXEN MEPHA; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; FEMALE; HUMAN; MALE; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ACETAMINOPHEN; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DICLOFENAC; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; YOUNG ADULT;

EID: 64749112779     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.02.042     Document Type: Article

References (36)

1. Abaci A., Yilmaz Y., Caliskan M., Bayram F., Cetin M., Unal A., and Cetin S. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb. Res. 116 (2005) 465-470
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
3. Blaicher A.M., Landsteiner H.T., Zwerina J., Leitgeb U., Volf I., and Hoerauf K. Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time. Anaesthesia 59 (2004) 1100-1103
4. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J., and VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343 (2000) 1520-1528
5. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., and Baron J.A. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352 (2005) 1092-1102
6. Capone M.L., Scialli M.G., Tacconelli S., Grana M., Ricciotti E., Renda G., Di Gregorio P., Merciaro G., and Patrignani P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J. Am. Coll. Cardiol. 45 (2005) 1295-1301
7. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., Vyas S.N., and FitzGerald G.A. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345 (2001) 1809-1817
8. Chan A.T., Manson J.E., Albert C.M., Chae C.U., Rexrode K.M., Curhan G.C., Rimm E.B., Willett W.C., and Fuchs C.S. Nonsteroidal anti-inflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113 (2006) 1578-1587
9. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tansik J., Elton T.S., and Simmons D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13926-13931
10. Coma-Canella I., Velasco A., and Castano S. Prevalence of aspirin resistance measured by PFA-100. Int. J. Cardiol. 101 (2005) 71-76
11. Cryer B., Berlin R.G., Cooper S.A., Hsu C., and Wason S. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin. Ther. 27 (2005) 185-191
12. Davi G., and Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357 (2007) 2482-2494
13. Farkouh M.E., Greenberg J.D., Jeger R.V., Ramanathan K., Verheugt F.W., Chesebro J.H., Kirshner H., Hochman J.S., Lay C.L., Ruland S., Mellein B., Matchaba P.T., Fuster V., and Abramson S.B. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen, or lumiracoxib. Ann. Rheum. Dis. 66 (2007) 764-770
14. Feuring M., Schultz A., Losel R., and Wehling M. Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. Semin. Thromb. Hemost. 31 (2005) 411-415
15. 2 as an amplifying signal for other agonists. Am. J. Cardiol. 68 (1991) 11B-15B
16. Fuchs I., Frossard M., Spiel A., Riedmüller E., Laggner A.N., and Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J. Thromb. Haemost. 4 (2006) 2547-2452
17. Funk C.D., Funk L.B., Kennedy M.E., Pong A.S., and FitzGerald G.A. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB. J. 5 (1991) 2304-2312
18. Garcia Rodriguez L.A., Varas-Lorenzo C., Maguire A., and Gonàlez-Pérez A. Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109 (2004) 3000-3006
19. Grundmann K., Jaschonek K., Kleine B., Dichgans J., and Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J. Neurol. 250 (2003) 63-66
20. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 332 (2006) 1302-1308
21. Lee Y.S., Kim H., Brahim J.S., Rowan J., Lee G., and Dionne R.A. Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain 129 (2007) 279-286
22. Livio M., Del Maschio A., Cerletti C., and de Gaetano G. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 23 (1982) 787-796
23. 2 synthase. Nat. Struct. Biol. 2 (1995) 637-643
24. 2 synthase cyclooxygenase active site. Biochemistry 35 (1996) 7330-7340
25. MacDonald T.M., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
26. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
27. Mitchell J.A., Lucas R., Vojnovic I., Hasan K., Pepper J.R., and Warner T.D. Stronger, inhibition by nonsteroidal anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB. J. 14 (2006) 2468-2475
28. Munsterhjelm E., Niemi T.T., Ylikorkala O., Neuvonen P.J., and Rosenberg P.H. Influence on platelet aggregation of i.v. parecoxib and acetaminophen in healthy volunteers. Br. J. Anaesth. 97 (2006) 226-231
29. Ouellet M., and Percival M.D. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch. Biochem. Biophys. 387 (2001) 273-280
30. Patrignani P., Sciulli M.G., Manarini S., Santini G., Cerletti C., and Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J. Physiol. Pharmacol. 50 (1999) 661-667
31. 2 synthase-1. Nature 367 (1994) 243-249
32. Rao G.H., Johnson G.G., Reddy K.R., and White J.G. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 3 (1983) 383-388
33. Strand V. Are COX-2-inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet 370 (2007) 2138-2151
34. Van Hecken A., Schwartz J.I., Depré M., De Lepeleire I., Dallob A., Tanaka W., Wynants K., Buntinx A., Arnout J., Wong P.H., Ebel D.L., Gertz B.J., and De Schepper P.J. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol. 40 (2000) 1109-1120
35. White W.B., Faich G., Whelton A., Maurath C., Ridge N.J., Verburg K.M., Geis G.S., and Lefkowith J.B. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am. J. Cardiol. 89 (2002) 425-430
36. Wuillemin W.A., Gasser K.M., Zeerleder S.S., and Lämmle B. Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency. Swiss Med. Wkly. 132 (2002) 443-448